Mymetics Realizes Successful Phase I Study with Its Innovative HIV Vaccine MYM-V101
Epalinges, Switzerland, 26 May 2011
Mymetics Corporation, a pioneer in the development of vaccines that use the human mucosal system, the body’s first line of defense, to prevent transmission of infectious diseases, announced today that its innovative HIV-1 (Human Immunodeficiency Virus type 1) vaccine proved to be safe and well tolerated and demonstrated a high level of immunogenicity in a Phase I trial involving 24 healthy women.
|Media Name||Media Type||Description||Download|
|110525 Final Press release HIV Phase I v long-clean||Download|